

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **AMENDMENT TO THE 2021 RESTRICTED SHARE AWARD SCHEME**

Reference is made to the announcement of the Company dated 24 August 2021 relating to the adoption of the restricted share award scheme of the Company.

Pursuant to the 2021 Scheme Rules, the scheme may be amended by a resolution of the Board, provided that such alterations or variations are made in compliance with the memorandum and articles of association of the Company, the Listing Rules and applicable laws.

### **AMENDMENT TO THE 2021 RESTRICTED SHARE AWARD SCHEME**

On 26 May 2022, the Board resolved to make an amendment to the definition of “Eligible Participant(s)” under the 2021 Restricted Share Award Scheme. In addition to allowing a grant of share awards to any director or employee of the Company or any of its subsidiaries, the definition of “Eligible Participant(s)” has been amended and expanded to also include any person or entity who has made significant contribution, or will potentially make significant contribution to, the development of the Group.

Save for the amendment specified above in this announcement, all other provisions of the 2021 Restricted Share Award Scheme remain unchanged.

# **REASONS FOR AND BENEFITS OF THE AMENDMENT TO THE 2021 RESTRICTED SHARE AWARD SCHEME**

The reasons for the amendment is to expand the scope of eligible participants that can receive grants of share awards under the 2021 Restricted Share Award Scheme to any person (not only a director or an employee of the Company or any of its subsidiaries) or entity who has made significant contribution, or will potentially make significant contribution to, the development of the Group, and to (i) provide such person(s) or entity(ies) with the opportunity to acquire proprietary interests in the Company, (ii) encourage such person(s) or entity(ies) to contribute towards enhancing the value of the Company and its shares for the benefit of the Company and its Shareholders as a whole, and (iii) provide the Company with a flexible means of incentivizing, rewarding, remunerating, compensating and/or providing benefits to such person(s) or entity(ies).

The Board is of the view that the amendment to the 2021 Restricted Share Award Scheme is in compliance with the memorandum and articles of association of the Company, the Listing Rules and applicable laws.

## **LISTING RULES IMPLICATION**

The 2021 Restricted Share Award Scheme is a discretionary scheme of the Company and that the scheme does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules. This announcement is made on a voluntary basis.

## **DEFINITION**

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

<b>Term</b>	<b>Definition</b>
“2021 Restricted Share Award Scheme”	the restricted share award scheme adopted on 23 August 2021, constituted by the rules thereof, in its present form or as amended from time to time in accordance with the provisions thereof;
“2021 Scheme Rules”	the rules of the 2021 Restricted Share Award Scheme in its present or any amended form;
“Board”	the board of directors of the Company;
“Company”	Genscript Biotech Corporation 金斯瑞生物科技股份有限公司* (Stock Code: 1548), a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the main board of the Stock Exchange;

“Director(s)”	director(s) of the Company;
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange;
“Shareholders”	the holders of shares of the Company;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 26 May 2022

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* *For identification purposes only*